Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Hannah Seemann, Nadja Jaekel, Susann Schulze, MD, Juliane Grimm, MD, Ole Vollstaedt, MD, Anja Haak, PhD, Dietger Niederwieser, MD PhD, Claudia Wickenhauser, MD, Haifa Kathrin Al-Ali, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-139311

Published: 2020

Journal Articles

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Tony Hennersdorf, Nadja Jaekel, Susann Schulze, MD, Dietrich Kaempfe, MD, Claudia Spohn, MD, Regina Moeller, MD, Maik Schwarz, MD, Hans-Juergen Hurtz, MD, Joern Ruessel, MD, Peter Tornow, Ute Neef, MD, Marion Schmalfeld, MD, Kathleen Jentsch-Ullrich, MD, Thoralf Lange, MD, Christian Junghanss, MD, Brigitte Kragl, MD, Haifa Kathrin Al-Ali, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-139366

Published: 2020

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Nadja Jaekel, Susann Schulze, MD, Udo Siebolts, MD, Anja Haak, PhD, Nikolaos Pazaitis, MD, Michael Cross, PhD, Dietger Niederwieser, MD, Mathias Hänel, MD, Georg Maschmeyer, MD, Maxi Wass, MD, Lukas Heukamp, MB PhD, Roopika Menon, Miriam Bertrand, Claudia Wickenhauser, MD, Oana Brosteanu, PhD, Haifa Kathrin Al-Ali, MD

Blood (2019) 134 (Supplement_1): 1420.

https://doi.org/10.1182/blood-2019-127865

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Hartmut Döhner, MD, Paresh Vyas, MD PhD, John F. Seymour, MD, Valeria Santini, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Haifa Kathrin Al-Ali, MD, Teresa Bernal del Castillo, MD PhD, John Morrill, MS, Stephen Songer, PharmD, Jerry Weaver, PhD, Barry S. Skikne, MD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 1638.

https://doi.org/10.1182/blood.V128.22.1638.1638

Published: 2016

Journal Articles

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Blood (2016) 128 (22): 1066.

https://doi.org/10.1182/blood.V128.22.1066.1066

Published: 2016

Journal Articles

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Lynda Foltz, MD FRCP, Giuseppe A. Palumbo, MD, Bruno Martino, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Anna Marina Liberati, MD, Philipp D. Le Coutre, MD, Alessandro M. Vannucchi, MD, Carmen Garcia-Hernandez, MD, Renato Tavares, MD, Martin Griesshammer, MD, Vikas Gupta, MD, Pia Raanani, MD, Pilar Giraldo, MD PhD, Catherine Bouard, Julian Perez Ronco, MD MBA, Sadhvi Khanna, MS, Andrey Zaritskey, MD

Blood (2016) 128 (22): 3107.

https://doi.org/10.1182/blood.V128.22.3107.3107

Published: 2016

Journal Articles

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Alessandro M. Vannucchi, MD, Heinz Gisslinger, MD, Claire N. Harrison, Haifa Kathrin Al-Ali, MD, Ester Pungolino, MD, Jean-Jacques Kiladjian, MD PhD, Francoise Boyer-Perrard, MD, Franck E. Nicolini, MD PhD, Shuyuan Mo, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Peter A. te Boekhorst

Blood (2015) 126 (23): 2817.

https://doi.org/10.1182/blood.V126.23.2817.2817

Published: 2015

Journal Articles

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

Renato Tavares, MD, Giuseppe A. Palumbo, MD, Philipp Le Coutre, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Jose Grasa Ullrich, MD, Massimo Breccia, MD, David Brittain, MD, Lynda Foltz, MD FRCP, Martin Griesshammer, MD, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Pilar Giraldo, MD PhD, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, MD MBA, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 2799.

https://doi.org/10.1182/blood.V126.23.2799.2799

Published: 2015

Journal Articles

Comprehensive Genomic Analysis Provides Further Evidence That Iron Overload Can Induce Genetic Instability in Myelodysplastic Syndromes

Gina Westhofen, Christina Ganster, Fabian Beier, MD, Tienush Rassaf, Haifa Kathrin Al-Ali, MD, Reingard Stuhlmann, Ulrike Bacher, Tim H. Brümmendorf, Ulrich Germing, MD, Norbert Gattermann, MD, Detlef Haase, MD

Blood (2015) 126 (23): 2842.

https://doi.org/10.1182/blood.V126.23.2842.2842

Published: 2015

Journal Articles

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Elizabeth O. Hexner, MD, Haifa Kathrin Al-Ali, MD, Lynda Foltz, MD FRCP, Michael Montgomery, MD, Wei Peng, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Hagop Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 1604.

https://doi.org/10.1182/blood.V126.23.1604.1604

Published: 2015

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, Mathias Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schultze, MD, Song-Yau Wang, MD, Oana Brosteanu, PhD, Dietger Niederwieser, MD

Blood (2015) 126 (23): 1346.

https://doi.org/10.1182/blood.V126.23.1346.1346

Published: 2015

Journal Articles

Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

Blood (2015) 126 (23): 2517.

https://doi.org/10.1182/blood.V126.23.2517.2517

Published: 2015

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Nadja Jaekel, MD, Song-Yau Wang, MD, Rainer Krahl, PhD, Karolin Hubert, Susann Schulze, MD, Rayk Stengel, PhD, Melanie Schneider, Martin Roskos, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali, MD

Blood (2015) 126 (23): 2014.

https://doi.org/10.1182/blood.V126.23.2014.2014

Published: 2015

Journal Articles

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): Results of the Phase I of the DRKS00004519 Study

Haifa Kathrin Al-Ali, MD, Rainer Krahl, PhD, Michael Cross, PhD, Hubert Karolin, Mrs, Nadja Jaekel, MD, Dietger Niederwieser, MD

Blood (2014) 124 (21): 2310.

https://doi.org/10.1182/blood.V124.21.2310.2310

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, MD, Martin Griesshammer, MD, Thomas Illmer, MD, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, MD, Renato S Tavares, MD, Alessandro M. Vannucchi, MD, Pilar Giraldo, MD PhD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Bayane Tannir, Julian Perez Ronco, MD, Jaggannath Ghosh, Haifa Kathrin Al-Ali, MD

Blood (2014) 124 (21): 3197.

https://doi.org/10.1182/blood.V124.21.3197.3197

Published: 2014

Journal Articles

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Blood (2014) 124 (21): 280.

https://doi.org/10.1182/blood.V124.21.280.280

Published: 2014

NARROW

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

Comprehensive Genomic Analysis Provides Further Evidence That Iron Overload Can Induce Genetic Instability in Myelodysplastic Syndromes

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): Results of the Phase I of the DRKS00004519 Study

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only